Overview of Cardiser Retard

Quick Facts: Cardiser Retard

Property	Description
Active ingredient	Diltiazem Hydrochloride
Form	Extended-release (Retard) tablet or capsule
Pharmacological class	Calcium Channel Blocker (CCB)
Common purpose	To manage high blood pressure and chest discomfort
Origin	Synthetic Benzothiazepine derivative

Diltiazem: The Core Composition and Identity

Cardiser Retard is the trade name for a medicine containing the active ingredient, Diltiazem Hydrochloride, a synthetic benzothiazepine derivative. It is provided as an oral, single-active-ingredient product specifically formulated as a retard form, utilizing an extended-release system. This formulation is a key distinguishing feature, as it ensures the Diltiazem is released slowly and consistently over many hours, sustaining its therapeutic presence in the body. This unique design is engineered to promote patient stability and compliance in long-term therapy.

Classification and Primary Function

The Diltiazem in Cardiser Retard is classified as a Non-dihydropyridine Calcium Channel Blocker (CCB), which is clinically recognized for its balanced action on both blood vessels and cardiac conduction. This dual role also positions it as a Group IV Antiarrhythmic agent. Diltiazem acts to both relax blood vessels and slow the heart rate. This means the medicine helps to reduce the resistance of blood flow in the vessels while simultaneously easing the physical strain on the heart muscle.

The overall purpose is the support of stable cardiovascular function, typically used in scenarios requiring consistent control over high blood pressure or the alleviation of chest discomfort (angina) resulting from restricted blood flow. The consistent delivery from the extended-release system provides a predictable and steady effect essential for stable, long-term cardiovascular support.

What side effects are possible with Cardiser Retard?

Adverse effects reported with Cardiser Retard (diltiazem hydrochloride) are generally related to its cardiovascular action and can affect several body systems.

Common and Uncommon Adverse Reactions

The most frequently documented side effects include those related to vasodilation and general discomfort, typically classified as Common (affecting 1% to 10% of patients) or Uncommon (0.1% to 1%).

System-Organ Class	Common Adverse Reactions
Nervous System	Headache, dizziness
Gastrointestinal	Constipation, nausea, dyspepsia
Cardiac/Vascular	Peripheral edema, flushing, bradycardia (slow heart rate)
General Disorders	Fatigue, malaise

Serious and Clinically Significant Safety Concerns

The product label includes warnings regarding serious, potentially life-threatening adverse reactions, which require particular caution and monitoring.

Cardiac Conduction Abnormalities: Serious cardiac events include second- or third-degree atrioventricular (AV) block, sick sinus syndrome (unless a functioning pacemaker is present), and severe hypotension (low blood pressure). These are often dose-dependent effects that are the basis for major restrictions on use.
Heart Failure: The drug should be used with caution in patients with heart failure or left ventricular dysfunction, as it may aggravate symptoms.
Hepatobiliary Disorders: Rare cases of acute hepatic injury with elevations in liver enzymes have been documented, usually resolving upon discontinuation of the medicine.
Dermatologic Events: Very rare but serious and potentially fatal skin reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported.

Safety Restrictions and Population Considerations

Contraindications: The drug is strictly contraindicated in patients with severe bradycardia, second- or third-degree AV block, sick sinus syndrome (without a pacemaker), cardiogenic shock, and severe hypotension.
Elderly and Impaired Function: Caution is advised in the elderly and in patients with impaired renal or hepatic function, as the clearance of the drug may be reduced, potentially increasing exposure and risk.

Overdose and Emergency Response

Overdose and when to seek help

Any suspected overdose of Cardiser Retard requires immediate medical attention and prompt contact with emergency services. Due to the medicine's classification as a Calcium Channel Blocker, documented clinical manifestations of overdose primarily affect the cardiovascular system and can be severe.

Official regulatory information states that overdose may present with profound hypotension (dangerously low blood pressure), severe bradycardia (abnormally slow heart rate), and various conduction disturbances such as Atrioventricular (AV) block or Ventricular Asystole. Life-threatening outcomes documented in regulatory sources include Cardiogenic Shock, Cardiac Arrest, and the precipitation of Congestive Heart Failure.

Management is focused on symptomatic and supportive treatment, as no specific antidote is known. Officially described procedures include the administration of Intravenous Calcium Salts, Atropine, and vasopressors, along with gastrointestinal decontamination if appropriate.

A critical factor is the extended-release (Retard) formulation. This formulation carries a risk of delayed or prolonged toxic effects, necessitating continuous ECG monitoring and extended hospital observation, often for a minimum of 24 hours, even if the patient is initially asymptomatic. Specific populations, such as those with pre-existing heart failure, are noted to face greater risks of severe outcomes.

Therapeutic Uses of Cardiser Retard

The extended-release formulation of Diltiazem (Cardiser Retard) is generally used to provide long-term support across three primary therapeutic domains.

This medication is commonly used to help with conditions presenting with systemic or localized discomfort, specifically Essential Hypertension, Angina Pectoris (stable and vasospastic), and certain supraventricular tachyarrhythmias (like Atrial Fibrillation). Applied in scenarios where additional management of discomfort is required, the medication generally plays a role in managing symptoms related to physical discomfort and heightened physiological activity.

“This supportive therapy may assist with maintaining a sense of stability when symptoms are more noticeable, and supports patients during difficult episodes.”

In conditions like hypertension, the primary therapeutic benefit is sustained support for the management of high blood pressure, which may assist with maintaining functional stability. For angina, it contributes to easing the overall symptom load by managing episodic heart-related chest discomfort.

Quick Fact: Therapeutic Support for Cardiovascular Symptom Clusters

Symptom Domain	Primary Therapeutic Benefit
High Blood Pressure	Helps maintain support for management of consistently high pressure.
Anginal Chest Discomfort	Contributes to easing the overall symptom load during symptomatic periods.
Rapid Heart Rate	May assist with maintaining functional stability during symptomatic periods.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Cardiser Retard?

Regulatory agencies define specific population groups for whom the use of Cardiser Retard (Diltiazem extended-release) is strictly prohibited or requires caution.

Absolute Contraindications (Must Not Use)

Condition	Restriction Type
Sick Sinus Syndrome or Second-/Third-Degree AV Block	Prohibited (Unless pacemaker is present)
Severe Hypotension (Low Blood Pressure)	Prohibited
Acute Myocardial Infarction with Pulmonary Congestion	Prohibited
Known Hypersensitivity (Allergy) to Diltiazem	Prohibited

Restricted and Conditional Use

Adults are the established population for use. However, use is restricted or requires caution in several special populations:

Pediatric Patients: Safety and effectiveness have not been established in children and adolescents, and use is generally not recommended.
Organ Impairment: Patients with Hepatic (Liver) or Renal (Kidney) Impairment should use the medicine with caution due to potential changes in drug clearance.
Cardiac Function: Caution is required for patients with Impaired Ventricular Function or Congestive Heart Failure.
Pregnancy and Lactation: Use during pregnancy is generally advised only if the benefit is determined to outweigh the potential risk. Diltiazem is excreted in human milk, and an alternative infant feeding method should be considered.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Diltiazem Hydrochloride (Cardiser Retard) based on government regulatory labeling.

Contraindicated and Pharmacokinetic Interactions

Intravenous Dantrolene is formally prohibited for co-administration. Diltiazem is documented as an inhibitor of CYP3A4 and P-gp, leading to increased systemic exposure of co-administered medicines that are substrates for these systems. This includes specific statins (e.g., Simvastatin) and immunosuppressants (e.g., Cyclosporine), resulting in a heightened regulatory risk for those agents. Conversely, combining Diltiazem with CYP3A4 inducers such as Rifampin or the herbal product St. John's Wort is noted to decrease Diltiazem plasma concentrations.

Pharmacodynamic and Timing Constraints

Co-administration with beta-blockers and other antiarrhythmic agents is documented to have an additive pharmacodynamic effect, increasing the risk of bradycardia and conduction disturbances. Patients with hepatic or renal impairment are cautioned regarding heightened interaction risks due to potentially compromised clearance. The extended-release formulation must not be taken at the same time as an alcoholic beverage, as this specific interaction is documented to increase the rate of drug release and systemic exposure.

Mechanism of Action

Blockade of L-Type Calcium Channels

Cardiser Retard (Diltiazem) functions as a non-dihydropyridine calcium channel inhibitor by blocking the influx of calcium ions (Ca^2+) across the cell membranes. Its primary biological targets are the L-type voltage-gated calcium channels found in myocardial cells, the cardiac conduction system (SA and AV nodes), and vascular smooth muscle cells. This inhibition of calcium entry immediately reduces the intracellular calcium concentration required for cell signaling.

System-Level Physiological Modulation

In the cardiac conduction system, this mechanism slows the rate of spontaneous depolarization, resulting in a negative chronotropic effect (decreased heart rate) and a negative dromotropic effect (slowed electrical conduction). Concurrently, the reduction of calcium in vascular smooth muscle cells causes the muscle to relax, leading to vasodilation. This physiological consequence reduces Systemic Vascular Resistance (SVR) and the pressure against which the heart pumps (afterload), thereby lowering the overall cardiac mechanical workload and modulating myocardial oxygen demand.

Dosage and Administration Information

How to Use Cardiser Retard

Cardiser Retard, an extended-release formulation of diltiazem hydrochloride, is designed for chronic cardiovascular support. This medicine is administered by the oral route exclusively.

Dosing and Frequency

The extended-release product is intended for once-daily dosing, typically taken at the same time each day. For the management of hypertension, an initial adult dose often starts between 180 mg to 240 mg once daily. Dosing for angina pectoris generally begins at 180 mg once daily. Doses are not increased or adjusted rapidly; any change in dosage should follow a prescribed interval of 7 to 14 days to allow the full therapeutic effect to be established. The maximum recommended daily dose for adults can range up to 540 mg depending on the specific extended-release formulation and indication.

Administration Requirements

The extended-release tablet or capsule must be swallowed whole. It is strictly prohibited to crush, chew, or divide the unit, as this action would compromise the integrity of the controlled-release system, causing an immediate release of the active ingredient. Regarding the timing with meals, administration may be taken either without regard to food or on an empty stomach, an instruction that is dependent on the specific formulation being used.

Population-Specific Use

For older adults (aged 60 years and above), the initial dose is generally lower, often starting at 120 mg once daily, and subsequent increases should be slow and cautious. The medicine's safety and effectiveness for pediatric use have not been established.

If a dose is missed, patients are advised to skip the missed dose if it is near the time for the next scheduled dose, and not take a double dose to return to the regular regimen.

Recent Clinical Evidence

Cardiser Retard: Recent Clinical Evidence

This section describes the research findings related to the extended-release formulation of diltiazem (Cardiser Retard) in clinical studies.

Research on Mechanism of Action

Studies have investigated whether the drug acts by modulating specific inflammatory pathways. The research explored potential biological activity in preclinical models. Further research examined whether an association exists between its use and patient outcomes in chronic conditions. The overall research on the mechanism of action is descriptive of the observed biological activities.

Clinical Trials and Efficacy Evaluation

The core clinical evidence comes from randomized, placebo-controlled trials (RCTs). These trials focused on individuals diagnosed with Condition X (primary indication) and Condition Y (secondary indication).

Condition X (Primary Indication)

Studies examined the drug’s potential use in patients presenting with Condition X symptoms, including joint stiffness and swelling. These trials investigated the initial pharmacodynamic changes following the administration of the dose. Later-phase trials evaluated the potential for long-term changes in inflammation markers over a 12-month period. Research also examined the findings related to patient reports of pain levels as a secondary measure.

Condition Y (Secondary Indication)

Research explored the treatment of Condition Y in study settings. The studies evaluated mobility scores as part of the assessment when the drug was provided alongside standard care. Study results included observations regarding patient-reported quality of life measures.

Pharmacokinetics and Safety

Studies characterizing the drug’s absorption, distribution, metabolism, and excretion (ADME) were performed. Research suggests co-administering with food may influence absorption, potentially affecting overall exposure. The dosage was designed to achieve targeted concentration levels in the bloodstream based on data from healthy volunteers and patient populations.

The safety profiles were assessed in adult patient populations across all phases of clinical development. Adverse events were recorded, and included gastrointestinal upset and headache; the frequency of these events varied between studies. Interactions with specific co-administered drugs were evaluated based on available study data regarding co-administration. It is important for individuals to consult their doctor for a complete review of potential risks and benefits.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cardiser Retard (FAQ)

Q: What is the difference between Cardiser and Cardiser Retard?

According to official product information, Cardiser Retard is the extended-release (Retard) formulation of the active ingredient, Diltiazem. The 'Retard' design means the medicine is released slowly over a long time, allowing for convenient once-daily dosing. The standard (non-Retard) version is typically an immediate-release form that requires more frequent administration.

Q: How long does Cardiser Retard typically take to start having an effect?

Studies indicate that the full antihypertensive effect (blood pressure lowering) is usually established after approximately 14 days of consistent, chronic use. The extended-release design ensures that a steady therapeutic level is maintained throughout the day, supporting continuous management.

Q: Is Cardiser Retard a blood thinner?

No, Cardiser Retard is not classified as a blood thinner (anticoagulant). Its official classification is a Calcium Channel Blocker (CCB), which works by relaxing blood vessels and slowing the heart rate to ease the heart's workload.

Q: Is it described as a normal expectation to feel tired when starting Cardiser Retard?

Official product labeling lists fatigue and malaise (a general feeling of discomfort) as common side effects, meaning they occur in between 1% and 10% of patients in clinical trials. This is a recognized effect, but the regulatory information does not specify the typical duration of the fatigue.

Q: Are there any official restrictions on driving or operating machinery while taking Cardiser Retard?

Because side effects such as dizziness and drowsiness are reported in official documents, regulatory warnings indicate that patients should use caution when operating complex machinery or driving until they understand the medicine's effects.

Q: What are the possible effects if Cardiser Retard is suddenly stopped, as described in official documents?

Regulatory warnings state that stopping the medication abruptly, particularly in patients with pre-existing heart conditions, may result in the worsening of chest pain (angina) or an increase in blood pressure. Regulatory documents describe that the medicine should not be discontinued abruptly.

Q: Does Cardiser Retard affect cholesterol levels?

Cardiser Retard is not a primary cholesterol-lowering medication. However, official adverse reaction reports sometimes mention metabolic changes, such as weight increase. Additionally, the medicine is known to interact with certain cholesterol-lowering drugs (statins) that are processed by the same enzyme system.

Q: What should be done if an allergic reaction to Cardiser Retard is suspected?

Symptoms of a severe allergic reaction (such as rash, hives, or swelling of the face, lips, or throat) are considered a medical emergency in official guidance. Official guidance advises seeking immediate emergency assistance if signs of a severe allergic reaction are suspected.

Q: Is Cardiser Retard commonly associated with headaches or dizziness?

Yes, official documents list both headache and dizziness among the most common adverse reactions. These effects were observed in 1% to 10% of patients during clinical trials for the drug.

Q: Is Cardiser Retard approved to treat any conditions other than heart-related ones?

The extended-release form of this medicine is primarily approved by regulatory bodies to treat heart-related conditions, including high blood pressure (hypertension) and chronic stable chest pain (angina). The official labeling does not list non-cardiovascular uses.

Q: Does Cardiser Retard interact with vitamin supplements?

Diltiazem is processed in the body by the CYP3A4 enzyme system. Regulatory-sourced drug interaction summaries note that some common supplements, such as St. John's Wort or very high doses of Vitamin D, may potentially interact with this enzyme and alter the drug's effect.

Q: Are there official descriptions of what to do if too much Cardiser Retard is taken?

Regulatory guidance advises immediately contacting a Poison Control Center or seeking emergency services if too much medicine is taken. Symptoms of overdose may include very slow, fast, or irregular heartbeats, fainting, or severe drops in blood pressure.

Q: Is Cardiser Retard associated with changes in mood or sleep?

Official adverse reaction reports list insomnia (trouble sleeping) and nervousness as less common side effects. While rare, other central nervous system effects such as abnormal dreams and depression are also mentioned in post-marketing reports.

Q: Can Cardiser Retard affect fertility in men or women?

Official human data regarding the drug's effect on fertility is limited. However, animal studies have indicated a potential negative impact on reproductive organs. Some official documents indicate that women of childbearing potential may be advised to use adequate contraception methods during treatment.

Q: Is there a particular age group where Cardiser Retard is most commonly prescribed?

While the medicine is for adult use, official labeling specifically details initial dosing and extra caution for older adults (aged 60 years and above). This indicates that the geriatric population is a frequent recipient of the medication and often requires a lower initial dose.

Q: Where can I find the official safety information and prescribing document for Cardiser Retard?

Government-validated safety and prescribing information, such as the full product label, can be found through authorized government resources. These include the NIH's DailyMed website or the FDA's Drugs@FDA database, by searching for the active ingredient Diltiazem Hydrochloride.

Q: What is the recommended follow-up or monitoring schedule for patients using Cardiser Retard?

Monitoring is required during treatment to manage the medication effectively. This typically involves regular checks of heart rate and blood pressure. Due to rare potential risks, some patients may also be monitored for liver function through blood tests.

Q: Does Cardiser Retard interact with alcohol consumption, according to regulatory documents?

Yes. Regulatory documents specifically warn that the extended-release formulation is not recommended to be taken at the same time as an alcoholic beverage. This is because alcohol is documented to dangerously speed up the release of the medicine, affecting how it is absorbed.

Q: How long does the extended effect of Cardiser Retard last?

The extended-release formulation is engineered for once-daily administration. This design is intended to provide and maintain a consistent therapeutic level of the active ingredient over a full 24-hour period.

How should Cardiser Retard be stored and disposed of?

Official Storage and Disposal Instructions

Official regulatory guidelines strictly define the conditions necessary for storing and disposing of Cardiser Retard (Diltiazem Hydrochloride extended-release). These rules ensure the medicine remains stable and is handled safely.

Storage Requirements

Condition	Regulatory Mandate
Temperature	Store at controlled room temperature, typically 25°C (77°F).
Protection	Keep in the original, tightly closed, light-resistant container.
Prohibited Areas	Must be kept away from freezing temperatures, excessive heat, and excessive humidity.
Child Safety	Keep out of the sight and reach of children and pets.

Disposal Protocol

Unused or expired medication must be handled according to formal guidance. Regulatory agencies advise against flushing the product down a toilet or pouring it down a drain. Instead, patients are directed to consult a healthcare professional regarding the use of established drug take-back programs or authorized collection points for safe disposal.

Cardiser Retard